Testing new drug combinations for pleural mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding a drug called fianlimab to another drug (cemiplimab) plus chemotherapy for people with a type of lung cancer called pleural mesothelioma. It aims to see if the combination is more effective than cemiplimab plus chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pleural mesothelioma (a type of cancer that affects the lining of the lungs) through a biopsy.
- Your cancer cannot be surgically removed and has been confirmed by a specialist team.
- You have not had chemotherapy or immunotherapy for this cancer before.
- You are between 18 and 75 years old.
- You have good kidney and liver function, and your blood counts are within certain ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial tests a combination of four medicines (two newer immune-boosting drugs, a blood vessel-blocking drug, and chemotherapy) to treat advanced mesothelioma—a serious lung cancer caused by asbestos exposure. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
This trial tests whether adding cadonilimab (an immune treatment) and bevacizumab (a medicine that targets blood supply to tumors) to standard chemotherapy can control pleural malignant mesothelioma that cannot be removed with surgery. It’s meant for people who have not yet started medicine for advanced disease and who meet health and blood test requirements.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy for people with malignant mesothelioma that cannot be treated with surgery or radiation. It may be an option whether you are starting treatment for the first time or have had up to three prior treatments.
Hear when a new Pleural Mesotheliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.